RT Journal Article
SR Electronic
T1 Rapid spread and high impact of the Variant of Concern P.1 in the largest city of Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.10.21255111
DO 10.1101/2021.04.10.21255111
A1 Barbosa, Gabriela Rodrigues
A1 Leão Moreira, Luiz Vinicius
A1 Oliveira Justo, Alberto Fernando
A1 Perosa, Ana Helena
A1 Cunha Chaves, Ana Paula
A1 Bueno, Mariana Sardinha
A1 de Souza Luna, Luciano Kleber
A1 Conte, Danielle Dias
A1 Almeida Carvalho, Joseane Mayara
A1 Prates, Janesly
A1 Dantas, Patricia Sousa
A1 Faico-Filho, Klinger Soares
A1 Camargo, Clarice
A1 Resende, Paola Cristina
A1 Mendonça Siqueira, Marilda
A1 Bellei, Nancy
YR 2021
UL http://medrxiv.org/content/early/2021/04/14/2021.04.10.21255111.abstract
AB First in Manaus in the Brazilian Northern region, the Variant of Concern P.1 traveled 3800 kilometers southeast to endanger Sao Paulo contributing to the collapse of the health system. Here, we show evidence of how fast the VOC P.1 has spread in the most populated city in South America.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundings to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in compliance with institutional guidelines, approved by the Ethics Committee of Sao Paulo Federal University (CEP/UNIFESP n. 29407720.4.0000.5505).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available in GISAID at https://www.gisaid.org/ reference number EPI_ISL_1464630 to EPI_ISL_1464677.